middle.news
Clarity Pharmaceuticals Completes Recruitment for Game-Changing Prostate Cancer Imaging Trial
9:53am on Thursday 17th of July, 2025 AEST
•
Healthcare
Read Story
Clarity Pharmaceuticals Completes Recruitment for Game-Changing Prostate Cancer Imaging Trial
9:53am on Thursday 17th of July, 2025 AEST
Key Points
Co-PSMA Phase II trial recruitment completed with 50 patients enrolled
Trial compares Clarity’s Cu-SAR-bisPSMA to standard Ga-PSMA-11 imaging
Focus on detecting prostate cancer recurrence in patients with low PSA
Positive prior data from PROPELLER and COBRA trials support Cu-SAR-bisPSMA
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE